The Flow Cytometry Core provides flow cytometry research support for Center members. The Core endeavors to provide high quality multi-color analysis, high-speed sorting (including biohazard sorting), education, consultation, application development, and data analysis. The Core has changed dramatically since the 2003 review. Use has increased 50%. To accommodate and permit this increase the Core has increased both hardware and staff. We have added four analytical cytometers ~ three 9-color CyAns and an 18-color LSRII and two sorters ~ a digital MoFlo XDP and Reflection. The Reflection which is configured for BSL-2+ sorting has been placed in specially renovated BSL-2+ space. We have also upgraded the FACSCalibur and FACScan to dual-laser, 5-color instruments. We have added two highly skilled 1.00 FTE positions to accommodate the increased use and to provide additional services. Notably, the Core's staff has an aggregate of 77 years of flow cytometry experience. In sum the Facility provides state-of-the-art analytical and sorting flow cytometers, expertise, education, consultation, data analysis, and ease of access (domain and website, central data storage and archiving, web-based scheduling). The Flow Cytometry Core is directed by Dr. Larry Arnold, the Director since the inception of the Core In 1982. In 2009 152 laboratories used the Core;Center members accounted for 76% of total use. The CCSG budget request is for $141,810 representing a CCSG contribution of 23% to the total projected budget. The requested increase is to help establish the new biohazard sorting facility which for the first-time will permit sorting of viable human materials and other pathogen containing materials by Center members. Our future plans are to concentrate on education of users to increase their competency and, thus, data quality. Our single technology investment plan is to evaluate the utility of the Amnis ImageStream imaging flow cytometry technology for our users.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-37
Application #
8392170
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$220,847
Indirect Cost
$72,664
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Au, Kin Man; Tripathy, Ashutosh; Lin, Carolina Pe-I et al. (2018) Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano 12:1544-1563
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468

Showing the most recent 10 out of 1525 publications